| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8432067 | Blood Reviews | 2016 | 15 Pages |
Abstract
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of lymphoma. We now recognize that DLBCL corresponds to a biologically heterogeneous family of diseases. Given the potential for cure for most DLBCL patients, appropriate diagnostic and staging evaluation and therapy are essential. Here we review areas of consensus as well as controversy in the evaluation, treatment and monitoring of patients with DLBCL and its related subtypes.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Paolo F. Caimi, Brian T. Hill, Eric D. Hsi, Mitchell R. Smith,